Editas Medicine, Inc. (EDIT)

Editas Medicine, Inc. (EDIT) scores 29 out of 100 on boothcheck's 11-model valuation framework. Verdict: Strong Avoid The estimated fair value is $0.25, representing a 89% premium to fair value. Quantitative score: 47/100. Qualitative score: 20/100.

Analysis includes bear, base, and bull fair value targets using DCF, Graham, regression, and 8 other valuation models.

View full EDIT analysis on boothcheck